Perspective
Our work in Perspective
-
Ending Health Insurance for Generic Drugs Would Save Patients Money
Eliminating insurance for generics might make patients nervous at first, but the payoff would be stable and affordable prices.
Categorized in -
Should the Government Restrict Direct-to-Consumer Prescription Drug Advertising? Six Takeaways on Their Effects.Â
Policymakers should proceed with caution as they design proposals to restrict advertising. Â
Categorized in -
Addressing Value Defects from Wasteful Services through Health Technology Assessment
All parts of the health care delivery system—ranging from biotechnologies to provider-led health care services—should be held equally accountable for providing valuable services to patients.
Categorized in -
Eli Lilly Is Cutting Insulin Prices and Capping Copays at $35 – 5 Questions Answered
The drugmaker’s move responded to the growing competition that has shaken up the insulin market in recent years.
Categorized in -
Many Americans Wrongly Assume They Understand What Normal Blood Pressure Is – and That False Confidence Can Be Deadly
Nearly half of all Americans ages 20 and up have high blood pressure. Yet research shows that most people in the US don’t know the cutoff numbers for healthy blood.
Categorized in -
California’s Marijuana Market is Crumbling
The nation’s largest state should rescue its disintegrating cannabis market by raising the cost to illicit producers and sellers, not by violating federal law.
Categorized in -
A Simple Way to Reduce Overdose Deaths: Tell Doctors When Patients Die
If they think that the crisis is happening elsewhere, clinicians may underestimate the risk.Â
Categorized in -
American Life in Realtime: a Benchmark Registry of Health Data for Equitable Precision Health
Applying artificial intelligence and machine learning to person-generated health data allows unprecedented assessment of associations between everyday life and health outcomes.
Categorized in -
The FDA is the Right Agency to Regulate CBD Products, but It Needs Help
Undefined and unregulated, CBD will continue to pose unnecessary risks and never reach its potential as a legitimate health supplement.
Categorized in
